This presentation focuses only on the randomized, controlled trial data of diabetes medications that explore the impact on cardiovascular outcomes. The majority of this presentation pertains to the following drug classes: DPP-4 inhibitors, SGLT-2, and GLP-1 medications. The main learning goal is to gain an understanding and awareness of the evidenced-based trials that evaluate Type 2 DM medications that meet expectations of cardiovascular risk reduction, and how the American Diabetes Association modified the clinical practice guidelines to reflect these important trial findings.
